Your search history is turned on.
Date: February 10, 2023 Jurisdictions: All jurisdictions
Form 27 FORM 51-102F3 Material Change Report Item 1. Name and Address of Company LexaGene Holdings Inc. 303-750 West Pender Street Vancouver, B.C. V6C 2T7 Telephone: 604-681-0084 Item 2. Date of Material Change News Release dated February 10, 2023 Item 3. News Release News Release dated February 10, 2023 was filed o...
LexaGene Holdings Announces Results of February 8, 2023 Annual General Meeting BEVERLY, Mass., Feb. 10, 2023 -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (LexaGene or the Company), a molecular diagnostics company that has commercialized the MiQLab System for automated multiplex PCR testing, announces the results of its annual general meeting held on February 8, 2023 (the AGM). The Comp...
Date: January 18, 2023 Jurisdictions: All jurisdictions
Form 27 FORM 51-102F3 Material Change Report Item 1. Name and Address of Company LexaGene Holdings Inc. 303-750 West Pender Street Vancouver, B.C. V6C 2T7 Telephone: 604-681-0084 Item 2. Date of Material Change News Release dated January 18, 2023 Item 3. News Release News Release dated January 18, 2023 was filed on ...
LexaGenes MiQLab System Detects Mycoplasma at Minute Levels, Rousing Additional Interest from BioPharma Customers BEVERLY, Mass., Jan. 18, 2023 -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (LexaGene or the Company), an innovative, molecular diagnostics company that has commercialized the MiQLabTM System for automated, genetic testing, is pleased to announce exciting news regarding the ab...
Date: January 17, 2023 Jurisdictions: All jurisdictions
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ...
EXHIBIT 31.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jeffrey Mitchell, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of LexaGene Holdings, Inc.; 2. Based on my knowledge, this report does not...
EXHIBIT 31.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dr. John Regan, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of LexaGene Holdings, Inc.; 2. Based on my knowledge, this report does not c...
Date: December 30, 2022 Jurisdictions: All jurisdictions
LEGAL_40321231.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Check the appropriate box: Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, ...
LEGAL_40388379.1 LEXAGENE HOLDINGS INC. 500 Cummings Ctr., Suite 4550, Beverly, MA 01915 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To be held on February 8, 2023 Dear Stockholder: The annual meeting of stockholders (the Annual Meeting) of LexaGene Holdings Inc. (the Company) will be held at Suite 1500, 1055 West Georgia Street, Vancouver, British Columbia, Ca...